Epigenetic genome modifications such as DNA methylation appear to be involved in various diseases. Here, we suggest that the levels of DNA methylation at the BssHII methylationsensitive restriction enzyme sites in the human REELIN (RELN) gene in the forebrain vary among individuals. Interestingly, although a statistically significant correlation between the levels of DNA methylation in RELN and age was detected in healthy individuals, no such correlations were seen in either schizophrenic or bipolar patients. In addition, reverse correlations between DNA methylation levels and RELN expression were also detected in postmortem brain RNA and on in vitro assay. These data suggest the possibility that epigenetic aberration from the normal DNA methylation status of RELN may confer susceptibility to psychiatric disorders.
Introduction
DNA methylation is an epigenetic modification on the mammalian genome, and cytosine residues in CpG dinucleotides appear to be favorable targets for methylation, resulting in C m pG. The process of DNA methylation and resultant C m pG appear to be involved in tissue-specific gene expression, chromatin modification and genomic imprinting, which play essential roles in development, cell proliferation and differentiation.
1,2 DNA methylation is also involved in various diseases, including cancer, 3 and may be associated with psychotic disorders such as schizophrenia. [4] [5] [6] [7] [8] To better understand the implications of DNA methylation in disease susceptibility, it is necessary to examine both the qualitative and quantitative status of DNA methylation within the genome.
In this study we developed a method by which relative levels of DNA methylation at methylationsensitive restriction enzyme sites within the genome can be determined. The method depends on methylation-sensitive restriction enzymes and real-time polymerase chain reaction (real-time PCR). We investigated this method in order to determine any associations between DNA methylation and psychotic disorders by measuring the levels of DNA methylation in genomic DNA from schizophrenic, bipolar and healthy subjects using samples kindly provided by the Stanley Medical Research Institute.
The results presented here suggest that the levels of DNA methylation at methylation-sensitive restriction enzyme sites in the human REELIN (RELN) gene vary among individuals, and that a possible correlation between the levels of DNA methylation in RELN and age occurs in healthy individuals, but not in either schizophrenic or bipolar patients. The present study suggests the possible association between epigenetic aberration in DNA methylation in RELN and psychiatric disorders.
Materials and methods

DNA and RNA samples
All genomic DNA and RNA samples examined here were extracted from human postmortem forebrains and were kindly provided by the Stanley Medical Research Institute. Samples were blinded (coded) during our experiments (determination of DNA methylation and examination of expression levels), and after reporting all experimental data to the Institute, we obtained information regarding the diagnoses of the coded subjects, and then analyzed our typing data using subject information (Table 1) .
Determination of relative DNA methylation levels Genomic DNA (0.5 mg) was digested with EcoRI and BssHII (methylation-sensitive restriction enzyme) at 371C overnight, collected by ethanol precipitation, and dissolved in 50 ml of TE. Digested DNA (60 ng/ test) was used as a template and was examined by means of real-time PCR using the following PCR primer sets:
For amplification of the control region of RELN;
For the test region of RELN, we carried out real-time PCR with a RELN probe that we designed:
Real-time PCR was carried out using the ABI PRISM 7000 or 7300 sequence detection system (Applied Biosystems, Foster City, CA, USA) with SYBR GREEN PCR Master Mix (for control region) or TaqMan Universal PCR Master Mix (for test region) according to the manufacturers' instructions and was repeated at least three times. Two individuals' samples were examined as controls for every PCR in order to normalize test data.
Cell culture
NTera2D1 cells were grown as described previously. 9 Cells (B7 Â 10 4 /cm 2 ) were treated with 10 À5 M alltrans-retinoic acid (RA) (SIGMA-ALDRICH, St Louis, MO, USA) in Dulbecco's modified eagle medium (SIGMA-ALDRICH) supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA), 100 U/ml penicillin (Invitrogen), and 100 mg/ml streptomycin (Invitrogen) for 3 weeks and reseeded (B5 Â 10 4 /cm 2 ), and further culture was carried out in the absence of RA.
Reverse transcription (RT)-(real-time) PCR Total RNAs isolated from the same postmortem forebrain specimens were also provided by the Stanley Medical Research Institute, and each RNA sample (B0.5. mg) was examined by means of reverse transcription (RT) -real-time PCR (RT-PCR) with TaqMan Gene Expression Assays (Applied Biosystems) using TaqMan probes specific for RELN (assay ID: Hs00192449_m1) and S18 rRNA (assay ID: Hs99999901_s1) as a control. The assay RT-PCR) was carried out using the ABI PRISM 7000 or 7300 sequence detection system (Applied Biosystems) with TaqMan One Step RT-PCR Master Mix Reagents kit (Applied Biosystems) according to the manufacturer's instructions and was repeated at least three times.
Construction of reporter plasmid and partial methylation
In order to construct a reporter plasmid carrying a putative RELN promoter linked to the Photinus luciferase reporter gene, the RELN promoter region from positions À525 to þ 333 relative to the RELN 
The resultant PCR product was digested with BglII and NcoI and was subjected to ligation with pGL3-control treated with the same restriction enzymes. The resultant plasmid possessing the putative human RELN promoter was designated 'pRELN-Luc'.
Partial methylation was carried out as follows: ten micrograms of the pRELN-Luc plasmid was treated with 4 U of CpG methylase (M. Sss I) (New England BioLabs, Inc., Beverly, MA, USA) in the presence of 2 Â , 1 Â and 0.2 Â provided S-adenosyl methionine at 371C for 6, 3 and 2 h, respectively. The treated plasmids were purified with a Wizard SV Gel and PCR clean-up system (Promega, Madison, WI, USA), and aliquots of the purified plasmids were subjected to digestion with BamHI and BssHII followed by real time PCR (1.25 ng each/test) for determination of DNA methylation levels. The PCR primer sets used were as follows:
For amplification of control region in the vector;
For test region in the partially methylated RELN, the same PCR primers, RC-F3 and RC-R3, and the RELN probe described above were used. Real-time PCR and analyses of methylation levels were also carried out as described above.
Transfection
The day before transfection, NTera2D1 cells treated with RA for 3 weeks were trypsinized, diluted with fresh medium without RA and antibiotics, and seeded into 24-well culture plates (approximately 0. Figure 1 Outline of typing strategy for determination of DNA methylation status in the genome. Genomic DNA was digested with EcoRI and BssHII (methylation-sensitive restriction enzyme), and was subjected to real-time PCR such that a target region carrying BssHII site(s) of interest could be amplified. In addition, a region adjacent to the target region, where no BssHII sites were present, was also amplified and used as a control to normalize the amplified target region. When the BssHII site of interest in the target region was methylated, digestion of the site with the enzyme was inhibited, resulting in successful PCR amplification of the target region during real-time PCR. In contrast, when the BssHII site was not methylated, complete digestion of the site by the enzyme occurred, resulting in little or no PCR amplification. Accordingly, the level of DNA methylation at the BssHII site of interest in the target region is quantitatively reflected by the efficiency of real-time PCR amplification, and the observed amount of target region was subjected to normalization against that of the control region. A schematic representation is shown. EcoRI, unmethylated BssHII and methylated BssHII sites are indicated by 'E', 'BII', and 'BII', respectively. Arrow heads indicate restriction enzymes. PCR primers and amplified products are indicated by arrows and bars, respectively.
pRELN-Luc plasmid and 0.05 mg of phRL-TK plasmid were applied. Cells were incubated for 4 h at 371C. After the 4-h incubation, 1 ml of the fresh culture medium without RA and antibiotics was added, and further incubation at 371C was carried out. Forty-eight hours after transfection, cell lysate was prepared and expression levels of luciferase were examined by the Dual-Luciferase reporter assay system (Promega) according to the manufacturer's instructions.
Results and discussion
Typing strategy for determination of DNA methylation status Figure 1 shows our typing strategy (method) for determination of DNA methylation status in the genome. Briefly, genomic DNA is digested with a methylation-sensitive restriction enzyme, and is then subjected to real-time PCR such that a target region carrying methylation-sensitive restriction enzyme site of interest can be amplified. In addition, regions adjacent to the target region, where no restriction enzyme sites are present, are also amplified and used as controls for normalization of the amplified target region. Compared with the method with bisulfitemodification of genomic DNA, the present method appears to have little or no bias from insufficient chemical modification of genomic DNA and biased PCR amplification with such a modified DNA in determination of methylation levels of target genes (or regions). Furthermore, this method, unlike a conventional Southern blot analysis with methylation-sensitive restriction enzymes, does not need a large amount of genomic DNA. Although the present system for determination of methylation levels appears to have the benefits that are not in conventional methods, the system profoundly depends upon methylation-sensitive restriction enzymes, by which investigation is usually restricted to the restriction enzyme sites; accordingly, this may be a major drawback of this method. By using the method we investigated the levels of DNA methylation in genomic DNA from schizophrenic, bipolar and healthy subjects to determine any associations between DNA methylation and psychotic disorders. The genomic DNA examined in this study was extracted from human postmortem forebrains of schizophrenic, bipolar and healthy individuals (35 samples each) (Table 1) , and was kindly provided by the Stanley Medical Research Institute.
DNA methylation status in RELN We examined the human REELIN (RELN) gene, as its putative promoter region (including exon 1) includes a GC-rich sequence containing several methylationsensitive restriction enzyme sites, 5 and because possible associations between this gene and psychotic disorders have been reported. [10] [11] [12] [13] [14] The methylation status at the BssHII sites (GCGCGC) in the promoter region was investigated using the above-described Relative levels of DNA methylation at BssHII sites in RELN were examined as described in Figure 1 . Data regarding the levels of the DNA methylation are averages of three independent examinations and are given in arbitrary methylation units (a.u.). Tests for equal variance were carried out to determine whether there were any correlations between DNA methylation levels and aging.
method. The results indicated that the relative levels of the DNA methylation varied among the schizophrenic, bipolar and healthy individuals. Because differences in the average levels of DNA methylation among the three groups did not reach statistical significance, further analyses stratified by age, gender, age at disease onset, life time alcohol and drug use and suicide status (Table 1) were carried out In this series of analyses, we identified an intriguing association; when DNA methylation levels and subject age were plotted in scatter graphs (Figure 2 ), a correlation between DNA methylation and age was seen in healthy individuals (r = 0.436, P < 0.01). It should be noted that no such correlation was seen in either schizophrenic or bipolar patients. In addition, it was observed that several patients under the age of 50 had higher levels of DNA methylation > 0.03 (a.u.) at the level of DNA methylation shown in Figure 2 : nine schizophrenia (25.7%) and seven bipolar (20.0%) cases met these criteria, but only three healthy individuals (8.6%) met these criteria. The difference in percentages between healthy individuals and either schizophrenic or bipolar patients, however, did not reach statistical significance owing to the small number of samples examined in this study. As for the other stratification analyses, we could not see their significant associations with the DNA methylation status in RELN.
Grayson et al. showed significant association of methylated cytosine at positions À139(CpApG) and À134(CpTpG) in RELN with schizophrenia by means of bisulfite-modification of genomic DNA followed by PCR amplification and sequence determination. 4 Our present study focused on the BssHII sites at positions þ 131, þ 227 and þ 229 in RELN. Therefore, different results between the previous and present studies may be attributable to the different positions examined.
Reverse correlation between the levels of DNA methylation and expression of the RELN gene A previous study with completely methylated RELN promoter by CpG methylase (M.Sss I) suggested that DNA methylation of the RELN promoter in vitro decreased its promoter activity; 5 but correlations between DNA methylation levels in RELN and RELN Figure 3 . Levels of RELN expression were normalized against those of S18 rRNA. Expression profile analysis was repeated twice independently (Exp.1 and Exp. 2). The results indicate that the expression of endogenous RELN is induced by RA treatment and that RELN expression peaks at around 3 weeks after RA treatment. Accordingly, we decided to use NTera2D1 cells treated with RA for 3 weeks host cells in the transient expression assay using partially methylated pRELN-Luc plasmids ( Figure 5 ). expression remained unanswered. It is of interest and importance to determine whether there is any association between DNA methylation levels and expression in RELN. Total RNAs isolated from the same postmortem forebrains were also provided by the Stanley Medical Research Institute, and the expression levels of RELN and 18S rRNA (control)
were examined by means of RT-PCR. In the samples prepared within 18 h of death (eight schizophrenia and four bipolar cases, and seven healthy controls), a reverse correlation between DNA methylation and RELN expression was detected (r = À0.63, P < 0.01), but no such correlation was seen in the samples prepared beyond 18 h after death (Figure 3 ). These Figure 5 Reverse correlation between DNA methylation levels and transcriptional expression of RELN. (a) Digestion profiles of partially methylated plasmids with restriction enzymes. The pRELN-Luc plasmid carrying Photinus luciferase driven by the human RELN promoter was partially methylated using a CpG methylase (M. Sss I), after which the levels of DNA methylation were determined as in Figure 1 . The resultant plasmids with various levels of DNA methylation, high (HMe)-, moderate (M-Me)-and low (L-Me)-level methylated pRELN-Luc, were further confirmed by restriction enzyme digestion with BssH II (BII) and Xba I (X) followed by agarose gel electrophoresis. A schematic restriction enzyme map of pRELN-Luc is shown. Non-methylated plasmids and size markers (HindIII-cut l DNA) are indicated by 'non-Me' and 'M', respectively. Note that the data also indicate that our typing method properly worked. (b) Reverse correlation between the levels of DNA methylation and expression of RELN. pRELN-Luc plasmids with various levels of DNA methylation were subjected to transfection together with phRL-TK encoding Renilla luciferase (control) into human teratocarcimona NTera2D1 cells treated with RA for 3 weeks, and in which endogenous RELN was being expressed (Figure 4 ). In addition, unmethylated SV40 promoter (in pGL3-Promoter) and no promoter (in pGL3-Basic) were also examined as positive and negative controls, respectively. Forty-eight hours after transfection, luciferase activities were examined. Test (Photinus) luciferase activity normalized against control (Renilla) luciferase activity and is given in arbitrary units (a.u.). Levels of DNA methylation are indicated as in Figure 2 and are given in arbitrary methylation units (a.u.).
observations suggest that the level of DNA methylation in RELN likely influences its expression; and the observations also suggest the possibility that the postmortem DNA and/or RNA might undergo substantial degradation within 18 h of death. To address the possibility, more extensive studies must be carried out.
To further evaluate the correlation between DNA methylation levels and expression in RELN, we constructed a reporter plasmid carrying the RELN promoter region linked to the Photinus luciferase gene. The reporter plasmid was subjected to partial methylation with CpG methylase (M.Sss I), after which the level of DNA methylation was determined using the above-described method. The resultant reporter plasmids with various levels of DNA methylation (Figure 5a ) and phRL-TK carrying Renilla luciferase (control) were cotransfected into NTera2D1 cells where endogenous RELN was expressed ( Figure  4 ), that is, in which transacting (transcription) factors necessary for the proper RELN expression could occur. After incubation, luciferase expression levels in the transfected cells were examined. As shown in Figure 5b , Photinus luciferase expression decreased with increased levels of DNA methylation in the RELN promoter; thus, the results indicate a reverse correlation between the levels of DNA methylation and expression of the RELN gene. Together with the results shown in Figure 3a , the data strongly suggest that the level of DNA methylation in RELN is significantly associated with its expression. The previous study using the RELN promoters which were completely methylated in vitro with various bacterial methylases suggested that DNA methylation participated in downregulation of RELN expression. 5 Therefore, it is most likely that DNA methylation in RELN is a key element functioning in regulation of the expression of RELN.
Our present data appear to be compatible with those of the previous studies using bisulfite-modification of genomic DNA, 4, 6 both suggesting the aberrant DNA methylation status of RELN in psychiatric disorders. In addition, recent studies also indicated that the mouse DNA methyltransferase 1 (Dnmt1) gene knockdown was accompanied by increased expression of Reln 15 and that protracted administration of L-methionine, a precursor of the methyl donor S-adenosyl-methionine in Dnmt1 catalytic activity, into mice led to decreased Reln expression, 7 suggesting possible inhibitions of the expression of Reln involving DNA methylation in vivo. Altogether, it is conceivable that RELN may undergo various levels of epigenetic modifications of DNA methylation, and that aberrant DNA methylation status in RELN leading to aberrant expression may confer susceptibility to psychiatric disorders.
Genetic and epigenetic factors conferring susceptibility to psychiatric disorders
The human RELN gene is mapped to chromosome 7q22, where few associations with human genetic diseases, except for a possible association with Finnish schizophrenia, 16 have been reported, whereas significant reductions in RELN transcripts and polypeptides in the brains of patients with psychiatric disorders have been repeatedly observed.
10-14 The present study indicates the possible association between epigenetic aberration in DNA methylation in RELN and psychiatric disorders; such aberration is probably undetectable using conventional genetic analyses. It is conceivable that even though genes were negative for associations with diseases on conventional genetic analysis, genes such as RELN may be involved in disease susceptibility through aberrant epigenetic modifications. Therefore, to identify the culprits conferring susceptibility to diseases, extensive studies focusing on both genetic factors and epigenetic factors are required.
